cisplatin + nedaplatin + albumin paclitaxel

This is a combination chemotherapy regimen consisting of three agents: - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. It is widely used for various solid tumors including sarcomas, carcinomas, lymphomas, and germ cell tumors. - **Nedaplatin** is another platinum-based agent similar to cisplatin but with a different toxicity profile; it also induces DNA crosslinking and apoptosis. Nedaplatin has been developed as an alternative to cisplatin with potentially reduced nephrotoxicity and gastrointestinal side effects. - **Albumin-bound paclitaxel (nab-paclitaxel)** is a nanoparticle formulation of the taxane paclitaxel bound to human albumin. This formulation allows higher dosing without the need for solvents that can cause hypersensitivity reactions. Paclitaxel stabilizes microtubules and inhibits their disassembly, blocking mitosis and inducing cell death. This combination has been studied as induction or neoadjuvant chemotherapy in several cancers such as esophageal squamous cell carcinoma and hypopharyngeal cancer[1][2][3][5]. The rationale for combining these drugs lies in their complementary mechanisms—two distinct platinum agents plus an antimicrotubule agent—potentially increasing efficacy while balancing toxicity profiles.